Impact du sémaglutide sur la composition corporelle et le comportement alimentaire des patients obèses
Year: 2024
Type: dissertation
Study design: Clinical Trial
Abstract: Introduction: Semaglutide is a GLP1 agonist receptor indicated in the management of obesity. Its effect on body composition is less studied. Material and method: We conducted a one-arm, open-label, interventional longitudinal study lasting one year. All patients were treated with semaglutide at the target dose of 2.4 mg weekly subcutaneously. Patients had 3 medical visits, one at baseline, one at month 7 and one at month 12. Body composition and eating habits were assessed at each visit. Results: Weight was reduced by 15.8 Kg. Fat mass accounted for most of the weight loss (11.9 kg, 78%). The percentage of fat mass decreased by 3.9% and visceral fat mass by 0.78 Kg, i.e. 25% of the initial value. Lean body mass decreased by 3.4 Kg (p < 0.0001) while grip strength increased by 3.5 Kg. There was no occurrence of sarcopenia under treatment, and the percentage of patients with dynapenia fell. Eating behaviour improved, with a reduction in compulsions, tachyphagia and hyperphagia. Conclusion: Semaglutide improves body composition and eating behavior in obese patients.
Source: HAL
Author: Alissou, Mathieu
Institution: Université de Rouen Normandie
Language: French
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7094803187
